EPCAM and cancer: Previous studies demonstrated that high affinity anti-EpCAM antibodies could cause toxic effects (phase I trials) [27, 28], while antibodies with moderate affinity to EpCAM-positive cancers efficiently mediated both antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity [29–31].